In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Investigational New Drugs
Esther F A BrandonJan H M Schellens

Abstract

Aplidine is a potent marine anti-cancer drug and is currently being investigated in phase II clinical trials. However, the enzymes involved in the biotransformation of aplidine and thus its pharmacokinetics are not known yet. To assess the biotransformation pathways of aplidine and their potential implications for human pharmacology and toxicology, the in vitro metabolism of aplidine was characterized using incubations with human plasma, liver preparations, cytochrome P450 (CYP) and uridine diphosphoglucuronosyl transferase (UGT) supersomes in combination with HPLC analysis and cytotoxicity assays with cell lines. Aplidine was metabolised by carboxyl esterases in human plasma. Using CYP supersomes and liver microsomes, it was shown that aplidine was metabolised mainly by CYP3A4 and also by CYP2A6, 2E1 and 4A11. Four metabolites were observed after incubation with human liver microsomes, one formed by CYP2A6 (C-demethylation) and three by CYP3A4 (hydroxylation and/or C-dealkylation). No conjugation was observed in human liver S9 fraction. However, the aplidine metabolites formed by CYP were further conjugated by the phase II enzymes UGT, GST and SULT. In accordance with the findings in microsomes and CYP supersomes, a significan...Continue Reading

References

Feb 1, 1993·Journal of Inorganic Biochemistry·J D HigginsS Fricker
Dec 8, 1998·European Journal of Drug Metabolism and Pharmacokinetics·P B DesaiS Kouzi
Dec 3, 1999·Journal of Clinical Pharmacy and Therapeutics·E Tanaka
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·R H Tukey, C P Strassburg
Nov 30, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·S L MacLeodN P Lan
Nov 30, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·P I MackenzieR A McKinnon
Jul 27, 2001·Current Drug Metabolism·F P Guengerich
Jun 7, 2003·Toxicology and Applied Pharmacology·Esther F A BrandonJan H M Schellens
Jul 10, 2003·Lancet Neurology·Charles J VechtErik B Wilms
Jul 29, 2003·Expert Opinion on Investigational Drugs·Gilberto SchwartsmannRafaelMartins Lopes
Aug 5, 2003·Journal of Biochemical and Molecular Toxicology·Stefan Wilkening, Augustinus Bader
Jun 19, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·M Teresa DonatoM José Gómez-Lechón
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond

❮ Previous
Next ❯

Citations

Feb 25, 2009·Investigational New Drugs·J H BeumerO van Tellingen
Sep 24, 2015·Drug Metabolism Reviews·Jayaprakasam Bolleddula, Swapan K Chowdhury
Oct 23, 2008·Cancer Chemotherapy and Pharmacology·Ricardo Nalda-MolinaJuan Jose Perez-Ruixo
Jan 24, 2017·Investigational New Drugs·L van AndelJ H Beijnen
Jun 23, 2018·Chemical Reviews·F Peter Guengerich, Francis K Yoshimoto
Mar 16, 2011·Environmental Science & Technology·Daniel O'DriscollKevin J James

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.